ResMed Announces Participation in the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022, at 4:00 p.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022, at 4:00 p.m. EST. The event will be available via live webcast, with a replay accessible for one year after the event. ResMed focuses on innovative healthcare solutions that treat chronic diseases, enhancing quality of life and reducing healthcare costs across more than 140 countries.
Positive
- CEO presentation at a prestigious healthcare conference may enhance investor confidence.
- Focus on innovative solutions could attract interest from investors and stakeholders.
Negative
- None.
Details
News Market Reaction – RMD
The recorded move for RMD in the trading session of this news was +0.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Dec. 30, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on Thursday, January 6, 2022, beginning at approximately 4:00 p.m. (Eastern Standard Time).
More information about this event, including a link to the live webcast, may be accessed by visiting https://investor.resmed.com. The webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible through January 6, 2023.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
| For investors | For media | ||
| Amy Wakeham | Jayme Rubenstein | ||
| +1 858.836.5000 | +1 858.836.6798 | ||
| investorrelations@resmed.com | news@resmed.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.